Study #2021-0047
A Phase 1, Multi-Center, Open-Label, Dose Finding Study of CC-96191 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
MD Anderson Study Status
Not Accepting
Treatment Agent
CC-96191
Description
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy. The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Leukemia, Myeloid
Study phase:
Phase I
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.